Management of complicated urinary tract infections in a referral center in Mexico

Int Urol Nephrol. 2015 Feb;47(2):229-33. doi: 10.1007/s11255-014-0883-y. Epub 2014 Nov 26.

Abstract

Background: Urinary tract infections are a common problem encountered by primary care, emergency physicians and urologists. A complicated urinary tract infection (CUTI) responds less effectively to the standard treatment. E. coli is the most common pathogen (40-70 %). In Mexico, there are ciprofloxacin resistance rates of 8-73 %, to trimethoprim/sulfamethoxazole 53-71 % and cephalosporins 5-18 %, with an ESBL E. coli prevalence of 10 %. For infections producing gas or purulent material, the percutaneous or endoscopic drainage is the standard.

Objective: To describe the management of patients with CUTIs, their specifically clinical course and eventual culture results determining the most common isolated microorganisms and their resistance.

Materials and methods: The clinical records of patients hospitalized with CUTIs from January 2012 to July 2013 were reviewed.

Results: One hundred and seventy-three patients were included. Acute pyelonephritis was the most common presentation (53.2 %). The most common microorganism was E. coli (83 %), with ESBL prevalence of 71.4 % and a resistance to quinolone, cephalosporin and trimethoprim of 89.7, 64.7 and 60.3 %, respectively. The most common factors associated with development of CUTIs were recent use of antibiotics (95.3 %) and obstructive uropathy (73.4 %). A total of 41 % received carbapenems and 40.5 % received minimally invasive treatments. Overall mortality was 2.9 %.

Discussion: There were a greater ESBL-producing pathogen prevalence and an over 50 % resistance to classically first-choice antibiotics. The minimally invasive treatments for complicated infections are fundamental; however, nephrectomy still has a role.

Conclusions: Wide-spectrum antimicrobial therapy and minimally invasive approaches are the most common treatments for CUTIs in our center, and a reevaluation regarding antibiotic use in Mexico needs to be done.

MeSH terms

  • Abscess* / microbiology
  • Abscess* / therapy
  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Drug Resistance, Multiple, Bacterial
  • Epididymitis / microbiology
  • Epididymitis / therapy
  • Escherichia coli Infections / diagnosis*
  • Escherichia coli Infections / drug therapy
  • Escherichia coli Infections / microbiology
  • Escherichia coli* / metabolism
  • Female
  • Humans
  • Length of Stay
  • Male
  • Mexico
  • Middle Aged
  • Orchitis / microbiology
  • Orchitis / therapy
  • Prostatitis / microbiology
  • Prostatitis / therapy
  • Pyelonephritis / microbiology
  • Pyelonephritis / therapy
  • Pyonephrosis / microbiology
  • Pyonephrosis / therapy
  • Risk Factors
  • Stents
  • Urinary Tract Infections / complications
  • Urinary Tract Infections / drug therapy*
  • Urinary Tract Infections / microbiology
  • Young Adult
  • beta-Lactamases / metabolism

Substances

  • Anti-Bacterial Agents
  • beta-Lactamases